Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 7/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | REN | P00797 | 1/20 | 0.54 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.52 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.52 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3866931 | 0.92 | OPRK1 (0.58) | OPRK1OPRM1OPRD1F2REN | |
| SCHEMBL3221787 | 0.90 | OPRK1 (0.59) | OPRK1OPRM1F2NTSR1NMUR2 | |
| SCHEMBL3221767 | 0.90 | OPRK1 (0.59) | OPRK1OPRM1F2NTSR1NMUR2 | |
| SCHEMBL3204393 | 0.88 | OPRK1 (0.59) | OPRK1OPRM1OPRD1F2REN | |
| SCHEMBL3204375 | 0.88 | OPRK1 (0.59) | OPRK1OPRM1OPRD1F2REN | |
| SCHEMBL8341612 | 0.85 | OPRD1 (0.55) | OPRK1OPRM1OPRD1F2NTSR1 | |
| SCHEMBL8341607 | 0.85 | OPRD1 (0.55) | OPRK1OPRM1OPRD1F2NTSR1 | |
| SCHEMBL30899147 | 0.84 | NMUR2 (0.59) | OPRM1OPRD1F2NMUR2NMUR1 | |
| SCHEMBL29679546 | 0.84 | OPRD1 (0.60) | OPRM1OPRD1F2 | |
| SCHEMBL31575698 | 0.83 | F2 (0.56) | OPRK1OPRM1OPRD1F2NMUR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962697-B2 | Bioreponsive polymers | INTERFACE BIOLOGICS INC. (CA) | 2015-02-24 | — | — | US | disclosed |
| US-20100041771-A1 | Bioreponsive Polymers | INTERFACE BIOLOGICS, INC. | 2010-02-18 | — | — | US | disclosed |
| EP-2040758-A2 | BIORESPONSIVE POLYMERS | Interface Biologics Inc. (CA) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008053362-A2 | BIORESPONSIVE POLYMERS | INTERFACE BIOLOGICS, INC. (CA) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041771-A1 | Bioreponsive Polymers | PEPD, PREP, DNPEP | OPRK1 2985/4885OPRM1 3402/4885OPRD1 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.